References
- US Cancer Statistics Working Group. United States Cancer Statistics: 1999–2009 Incidence and Mortality Web-based Report. Atlanta, GA, USA: Department of Health and Human Services, Centers for Disease Control and Prevention and National Cancer Institute; 2013. Available from: http://www.cdc.gov/uscs. Accessed October 16, 2013.
- American Cancer Society. Breast Cancer Facts and Figures 2012. Atlanta, GA, USA: American Cancer Society, Inc.; 2012. Available from: http://www.cancer.org/acs/groups/content/@epidemiologysurveilance/documents/document/acspc-031941.pdf. Accessed April 3, 2014.
- National Cancer Institute. Treatment options for HER2-positive breast cancer expand and evolve. Bethesda, MD, USA: National Cancer Institute; 2012. Available from: http://www.cancer.gov/ncicancerbulletin/101612/page2. Accessed September 16, 2013.
- Kaufman PA, Brufsky AM, Mayer M, et al. Treatment patterns and clinical outcomes in elderly patients with HER2-positive metastatic breast cancer from the registHER observational study. Breast Cancer Res Treat. 2012;135:875–883.
- Incorvati JA, Shah S, Mu Y, Lu J. Targeted therapy for HER2 positive breast cancer. J Hematol Oncol. 2013;6:38.
- US Food and Drug Administration. FDA approves Perjeta for neoadjuvant breast cancer treatment (Press release). Available from: http://www.fda.gov/newsevents/newsroom/pressannouncements/ucm370393.htm. Accessed April 3, 2014.
- Sullivan R, Peppercorn J, Sikora K, et al. Delivering affordable cancer care in high-income countries. Lancet. 2011;12:933–980.
- Montero AJ, Eapen S, Gorin B, Adler P. The economic burden of metastatic breast cancer: a US managed care perspective. Breast Cancer Res Treat. 2012;134:815–822.
- Ray S, Bonthapally V, McMorrow D, Bonafede M, Landsman-Blumberg P. Patterns of treatment, health care utilization and costs by lines of therapy in metastatic breast cancer in a large insured US population. J Comp Eff Res. 2013;2:195–206.
- Campbell JD, Ramsey SD. The costs of treating breast cancer in the US: a synthesis of published evidence. Pharmacoeconomics. 2009;27:199–209.
- Vera-Llonch M, Weycker D, Glass A, et al. Health care costs in women with metastatic breast cancer receiving chemotherapy as their principal treatment modality. BMC Cancer. 2011;11:250.
- Lage MJ, Borker R, Barber B, Gao S. Health care costs in postmenopausal women with hormone-positive metastatic breast cancer. J Med Econ. 2010;13:691–697.
- Breast. In: Edge SB, Byrd DR, Compton CC, et al, editors. AJCC Cancer Staging Manual. 7th ed. New York, NY, USA: Springer: 2010.
- Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol. 1992;45:613–619.
- Hines RB, Chatla C, Harvey L. Predictive capacity of three comorbidity indices in estimating mortality after surgery for colon cancer. J Clin Oncol. 2009;27:4339–4345.
- Lin DY, Wei LJ, Ying Z. Model-checking techniques based on cumulative residuals. Biometrics. 2002;58:1–12.
- Allen JM. Economic/societal burden of metastatic breast cancer: a US perspective. Am J Manag Care. 2010;16:697–704.